Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
复制标题
黄体生成素释放激素激动剂治疗的睾酮水平低于手术去势：质谱法获得的新见解。
DOI：
10.1016/j.juro.2011.12.063
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
A. Vis
中科院分区：
文献类型：
--
作者：
T. M. van der Sluis;H. Bui;Eric J.H. Meuleman;A. Heijboer;Jeroen F. Hartman;N. V. van Adrichem;E. Boevé;W. de Ronde;R. V. van Moorselaar;A. Vis
目的：对于晚期或转移性前列腺癌，推荐采用双侧睾丸切除术（手术去势）或促黄体生成素释放激素激动剂治疗（药物去势）。两种方法的目的都是将血清睾酮浓度降低至去势水平，目前定义为低于50 ng/dl。以前的研究结果是基于睾酮免疫测定，在低范围内准确度不足。在这项研究中，我们重新评估血清睾酮浓度的男性雄激素剥夺治疗使用同位素稀释-液相色谱-串联质谱法，一个准确的方法测量睾酮在castrate range.Materials和MethodsSubjects进行手术去势（34）或接受促黄体生成素释放激素激动剂（32）。在手术后或开始促黄体生成素释放激素激动剂治疗后3个月以上获得血清样本。使用同位素稀释-液相色谱-串联质谱法测定睾酮水平。二氢表雄酮硫酸盐，雄烯二酮，性激素结合球蛋白和benzobin B levels determined.ResultsAll科目血清睾酮值小于50 ng/dl和97%的睾酮浓度小于20 ng/dl。药物去势男性的睾酮水平（中位数4.0 ng/dl，范围小于2.9至20.2）显著低于手术去势男性（中位数9.2 ng/dl，范围小于2.9至28.8，p <0.001）。无差异被发现在硫酸脱氢表雄酮，雄烯二酮和性激素结合球蛋白水平之间的组，而bisobin B水平显着较高的促黄体生成素释放激素激动剂治疗group.ConclusionsUsing一个准确的技术睾酮测量，促黄体生成素释放激素激动剂治疗的主题有显着降低睾酮浓度比男性谁接受手术去势。这些发现的临床相关性仍有待确定。
PurposeAndrogen deprivation therapy by bilateral orchiectomy (surgical castration) or luteinizing hormone-releasing hormone agonist therapy (medical castration) is recommended for advanced or metastatic prostate cancer. Both methods aim at reducing serum testosterone concentrations to a castrate level which is currently defined as less than 50 ng/dl. The results of previous studies are based on testosterone immunoassays that have insufficient accuracy in the low range. In this study we reevaluated serum testosterone concentrations in men on androgen deprivation therapy using isotope dilution-liquid chromatography-tandem mass spectrometry, an accurate method of measuring testosterone in the castrate range.Materials and MethodsSubjects underwent surgical castration (34) or received a luteinizing hormone-releasing hormone agonist (32). Serum samples were obtained more than 3 months after surgery or initiation of luteinizing hormone-releasing hormone agonist therapy. Testosterone levels were determined using isotope dilution-liquid chromatography-tandem mass spectrometry. Dihydroepiandrosterone sulfate, androstenedione, sex hormone-binding globulin and inhibin B levels were determined.ResultsAll subjects had serum testosterone values less than 50 ng/dl and 97% had testosterone concentrations less than 20 ng/dl. Medically castrated men had significantly lower testosterone levels (median 4.0 ng/dl, range less than 2.9 to 20.2) than those surgically castrated (median 9.2 ng/dl, range less than 2.9 to 28.8, p <0.001). No difference was found in dehydroepiandrosterone sulfate, androstenedione and sex hormone-binding globulin levels between the groups, whereas inhibin B levels were significantly higher in the luteinizing hormone-releasing hormone agonist treated group.ConclusionsUsing an accurate technique for testosterone measurement, subjects on luteinizing hormone-releasing hormone agonist therapy had significantly lower testosterone concentrations than men who underwent surgical castration. The clinical relevance of these findings remains to be determined.
促卵泡激素受体：泌尿生殖系统恶性肿瘤的新靶点。
DOI：
10.1016/j.urolonc.2012.03.005
发表时间：
2013-11
期刊：
Urologic oncology
影响因子：
--
作者：
Gartrell BA;Tsao CK;Galsky MD
通讯作者：
Galsky MD